Please assess the completion status of the following clinical trial:

Trial Title: SCHEDULE Follow Up Visit 5-7 yr

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who participated in the SCHEDULE 12-month main study, and who completed the 3 year follow-up visit~* Patients who are coming for a regular annual clinic visit 5 to 7 years after randomization in the main study~* Obtaining of a separate signed patient informed consent will be required for participation in this follow-up examination.~Exclusion Criteria:~* Patients with a retransplanted heart since the original SCHEDULE study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EVEROLIMUS (Type: EXPERIMENTAL): patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
- Control (Type: ACTIVE_COMPARATOR): patients received standard CsA, MMF and corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).